Literature DB >> 21796531

Global identification of androgen response elements.

Charles E Massie1, Ian G Mills.   

Abstract

Chromatin immunoprecipitation (ChIP) is an invaluable tool in the study of transcriptional regulation. ChIP methods require both a priori knowledge of the transcriptional regulators which are important for a given biological system and high-quality specific antibodies for these targets. The androgen receptor (AR) is known to play essential roles in male sexual development, in prostate cancer and in the function of many other AR-expressing cell types (e.g. neurons and myocytes). As a ligand-activated transcription factor the AR also represents an endogenous, inducible system to study transcriptional biology. Therefore, ChIP studies of the AR can make use of treatment contrast experiments to define its transcriptional targets. To date several studies have mapped AR binding sites using ChIP in combination with genome tiling microarrays (ChIP-chip) or direct sequencing (ChIP-seq), mainly in prostate cancer cell lines and with varying degrees of genomic coverage. These studies have provided new insights into the DNA sequences to which the AR can bind, identified AR cooperating transcription factors, mapped thousands of potential AR regulated genes and provided insights into the biological processes regulated by the AR. However, further ChIP studies will be required to fully characterise the dynamics of the AR-regulated transcriptional programme, to map the occupancy of different AR transcriptional complexes which result in different transcriptional output and to delineate the transcriptional networks downstream of the AR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796531     DOI: 10.1007/978-1-61779-243-4_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells.

Authors:  D M Altintas; M S Shukla; D Goutte-Gattat; D Angelov; J P Rouault; S Dimitrov; Jacques Samarut
Journal:  Mol Endocrinol       Date:  2012-07-06

2.  Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.

Authors:  Siqi Xu; Xiaoyan Wu; Zhihua Tao; Hongsheng Li; Chenliang Fan; Songjin Chen; Jianwei Guo; Yao Ning; Xuqi Hu
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

3.  Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.

Authors:  Paula Paulo; Franclim R Ribeiro; Joana Santos; Diana Mesquita; Mafalda Almeida; João D Barros-Silva; Harri Itkonen; Rui Henrique; Carmen Jerónimo; Anita Sveen; Ian G Mills; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

Review 4.  From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.

Authors:  Ekaterina Nevedomskaya; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

Review 5.  The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.

Authors:  Jelani C Zarif; Cindy K Miranti
Journal:  Cell Signal       Date:  2016-01-29       Impact factor: 4.315

6.  Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.

Authors:  Nelma Pertega-Gomes; Jose R Vizcaino; Sergio Felisbino; Anne Y Warren; Greg Shaw; Jonathan Kay; Hayley Whitaker; Andy G Lynch; Lee Fryer; David E Neal; Charles E Massie
Journal:  Oncotarget       Date:  2015-08-28

7.  Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.

Authors:  Maria J Camões; Paula Paulo; Franclim R Ribeiro; João D Barros-Silva; Mafalda Almeida; Vera L Costa; Nuno Cerveira; Rolf I Skotheim; Ragnhild A Lothe; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

Review 8.  Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?

Authors:  Hannelore V Heemers
Journal:  Int J Biol Sci       Date:  2014-06-01       Impact factor: 6.580

9.  The co-chaperone p23 promotes prostate cancer motility and metastasis.

Authors:  Laia Querol Cano; Derek N Lavery; Soraya Sin; Emma Spanjaard; Greg N Brooke; Jessica D Tilman; Ahmed Abroaf; Luke Gaughan; Craig N Robson; Rakesh Heer; Francesco Mauri; Johan de Rooij; Keltouma Driouch; Charlotte L Bevan
Journal:  Mol Oncol       Date:  2014-09-06       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.